fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Nippon India Pharma Fund Vs SBI Pharma Fund

Nippon India Pharma Fund Vs SBI Healthcare Opportunities Fund

Updated on January 24, 2023 , 5295 views

Nippon India Pharma Fund (Formerly known as Reliance Pharma Fund) Vs SBI Healthcare Opportunities Fund both the schemes are a part of sectoral Equity Funds. These schemes invest their fund money in equity and equity-related instruments of pharmaceutical and healthcare companies. These companies are into Manufacturing of medicines and other pharmaceutical products. Being sector-related funds, the risk-appetite of these schemes is high. India being a country with large population, the demand for medicines is high. Though both funds belong to the same category yet; both of them differ in various accounts such as performance, AUM, and much more. So, let us compare and understand the differences between Reliance/Nippon India Pharma Fund Vs SBI Healthcare Opportunities Fund.

Nippon India Pharma Fund (Formerly Reliance Pharma Fund)

Important Information

From October 2019, Reliance Mutual Fund has been renamed as Nippon India Mutual Fund. Nippon Life has acquired majority (75%) stakes in Reliance Nippon Asset Management (RNAM). The company will continue to run its operations without any change in structure and management.

This scheme is managed by Nippon Mutual Fund and was incepted on June 05, 2004. This scheme invests its fund money in equity and fixed Income instruments of pharma and associated companies and strives to earn consistent returns thereby. The risk appetite of Reliance/Nippon India Pharma Fund is High. This fund’s Portfolio is a combination of large cap and mid-cap companies. Mr. Shailesh Raj Bhan is the fund manager who overlooks the performance of Nippon India Pharma Fund. As on January 31, 2018, some of the shares that were part of Nippon India Pharma Fund’s portfolio consisted of Thyrocare Technologies Limited, Sun Pharmaceutical Industries Limited, Cipla Limited, and Torrent Pharmaceuticals Limited. It is an open-ended scheme.

SBI Healthcare Opportunities Fund (Erstwhile SBI Pharma Fund)

SBI Healthcare Opportunities Fund (earlier known as SBI Pharma Fund) is an open-ended that invest in a diversified portfolio of equity and equity related securities in Healthcare space. This scheme is managed by SBI Mutual Fund and was launched in the year 1999. This scheme uses S&P BSE Healthcare Index as its benchmark to construct its portfolio. Its aim is to provide atmost growth opportunities to investors by Investing in an actively managed portfolio predominantly consisting of pharma stocks. SBI Healthcare Opportunities Fund is solely managed by Mr. Tanmaya Desai. The scheme is suitable for investors who are willing to take a high-risk and are confident about the growth aspects in the healthcare sector. As on January 31, 2018, some of the companies that were part of SBI Healthcare Opportunities Fund’s portfolio included DIVI’s Laboratories Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, and Strides Shasun Limited.

Nippon India Pharma Fund Vs SBI Healthcare Opportunities Fund

Though both the schemes belong to the same sector yet there exist differences between them. So, let us compare and understand the differences between both the schemes based on various parameters that are divided into four sections, namely, Basics Section, Performance Section, Yearly Performance Section, and Other Details Section.

Basics Section

The comparable elements that form part of basics section include Scheme Category, Fincash Rating, and Current NAV. Based on the scheme category, it can be said that both the scheme belong to the same category that is Equity Sectoral. The next element is Fincash Rating as per which both the funds are rated as 2-Star. However, the comparison of Current NAV shows that there is a difference between the two. The NAV of Nippon India Pharma Fund is higher than SBI Healthcare Opportunities Fund. As on March 01, 2018, the NAV of Nippon’s scheme was approximately INR 140 while of SBI’s scheme was approximately INR 123. The summary of basics section is tabulated as follows.

Parameters
BasicsNAV
Net Assets (Cr)
Launch Date
Rating
Category
Sub Cat.
Category Rank
Risk
Expense Ratio
Sharpe Ratio
Information Ratio
Alpha Ratio
Benchmark
Exit Load
Nippon India Pharma Fund
Growth
Fund Details
₹276.805 ↓ -3.24   (-1.16 %)
₹4,563 on 31 Dec 22
5 Jun 04
Equity
Sectoral
35
High
1.96
-0.98
0.61
0.8
Not Available
0-1 Years (1%),1 Years and above(NIL)
SBI Healthcare Opportunities Fund
Growth
Fund Details
₹219.852 ↓ -0.94   (-0.42 %)
₹1,660 on 31 Dec 22
31 Dec 04
Equity
Sectoral
34
High
2.16
-0.7
0.56
4.82
Not Available
0-15 Days (0.5%),15 Days and above(NIL)

Performance Section

The performance section compares the Compounded Annual Growth Rate or CAGR returns of both the schemes at various intervals. Some of these time intervals include 1 Month Return, 3 Month Return, 1 Year Return, and 5 Year Return. Comparison of CAGR returns shows that at most time periods, the returns of Nippon India Pharma Fund are higher than the returns of SBI Healthcare Opportunities Fund. The table given below summarizes the performance comparison of both the schemes.

Parameters
Performance1 Month
3 Month
6 Month
1 Year
3 Year
5 Year
Since launch
Nippon India Pharma Fund
Growth
Fund Details
-3%
-3%
2.4%
-3.5%
20.9%
13.5%
19.5%
SBI Healthcare Opportunities Fund
Growth
Fund Details
-0.9%
-1.3%
6%
-0.1%
21.2%
10.8%
13.6%

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Yearly Performance Section

Yearly Performance Section compares the absolute returns between both the schemes for a particular year. In this section, for certain years, the performance of SBI Healthcare Opportunities Fund is better than the performance of Reliance/Nippon India Pharma Fund and vice versa. The yearly performance section’s summary is tabulated as follows.

Parameters
Yearly Performance2022
2021
2020
2019
2018
Nippon India Pharma Fund
Growth
Fund Details
-9.9%
23.9%
66.4%
1.7%
3.6%
SBI Healthcare Opportunities Fund
Growth
Fund Details
-6%
20.1%
65.8%
-0.5%
-9.9%

Other Details Section

It is the last section of comparison between both the schemes. The parameters forming part of this section include AUM, Minimum SIP investment, Minimum Lumpsum Investment, and Exit Load. The comparison of AUM reveals that the Nippon scheme's AUM is more than the SBI’s scheme. As on July 23, 2021, the SBI healthcare opportunity fund was INR 2003.7 Crores and of Nippon India Pharma Fund was ₹ 5446.95 Crores. Moreover, the Minimum SIP Investment is also different for both the schemes. The Minimum SIP Investment for Nippon’s scheme is INR 100 and for SBI’s scheme is INR 500. With respect to the exit load, Nippon India Pharma Fund charges 1% if the Redemption is done within one year from the date of purchase and no charges after one year. SBI Healthcare Opportunities Fund, on the other hand, charges 0.5% if the redemption is done within 15 days from the date of purchase and no load after it. The summary of this section is as follows.

Parameters
Other DetailsMin SIP Investment
Min Investment
Fund Manager
Nippon India Pharma Fund
Growth
Fund Details
₹100
₹5,000
Sailesh Raj Bhan - 17.76 Yr.
SBI Healthcare Opportunities Fund
Growth
Fund Details
₹500
₹5,000
Tanmaya Desai - 11.59 Yr.

Growth of 10k Investments over the years

Growth of 10,000 investment over the years.
Nippon India Pharma Fund
Growth
Fund Details
DateValue
31 Dec 17₹10,000
31 Dec 18₹10,364
31 Dec 19₹10,538
31 Dec 20₹17,540
31 Dec 21₹21,738
31 Dec 22₹19,585
Growth of 10,000 investment over the years.
SBI Healthcare Opportunities Fund
Growth
Fund Details
DateValue
31 Dec 17₹10,000
31 Dec 18₹9,011
31 Dec 19₹8,966
31 Dec 20₹14,869
31 Dec 21₹17,865
31 Dec 22₹16,790

Detailed Assets & Holdings Comparison

Asset Allocation
Nippon India Pharma Fund
Growth
Fund Details
Asset ClassValue
Cash0.36%
Equity99.64%
Equity Sector Allocation
SectorValue
Health Care99.64%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
15%₹732 Cr7,000,976
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
9%₹422 Cr3,700,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
8%₹397 Cr885,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
7%₹345 Cr4,500,025
Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIA
5%₹262 Cr129,321
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
5%₹246 Cr520,772
↑ 100,000
Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 30 Jun 17 | NH
5%₹221 Cr2,981,429
↓ -19,566
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
5%₹221 Cr650,000
Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Sep 20 | TORNTPHARM
5%₹216 Cr1,300,857
↓ -165,000
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA
3%₹164 Cr3,500,000
Asset Allocation
SBI Healthcare Opportunities Fund
Growth
Fund Details
Asset ClassValue
Cash2.69%
Equity96.94%
Equity Sector Allocation
SectorValue
Health Care89.19%
Basic Materials7.75%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA
16%₹282 Cr2,700,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH
10%₹171 Cr3,800,000
↓ -7,818
Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 500087
9%₹164 Cr1,440,000
Aether Industries Ltd (Basic Materials)
Equity, Since 31 May 22 | 543534
6%₹108 Cr1,200,000
↑ 100,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 20 | APOLLOHOSP
5%₹95 Cr200,000
↓ -20,000
Global Health Ltd (Healthcare)
Equity, Since 31 Oct 22 | MEDANTA
5%₹91 Cr2,000,000
↑ 2,000,000
Rainbow Childrens Medicare Ltd (Healthcare)
Equity, Since 30 Apr 22 | 543524
5%₹86 Cr1,160,000
↓ -40,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
4%₹68 Cr200,000
↓ -40,000
Abbott India Ltd (Healthcare)
Equity, Since 31 Mar 19 | ABBOTINDIA
4%₹65 Cr32,000
Medplus Health Services Ltd (Healthcare)
Equity, Since 31 Dec 21 | 543427
4%₹62 Cr911,178

Thus, from the above parameters, it can be said that there are a lot of differences between both the schemes. However, individuals should be careful while investing in any of the schemes. they should understand the scheme’s modalities thoroughly and check whether it matches with their objectives or not. People, if required, can also consult a financial advisor. This will help them to ensure that their investment reaps them the required results.

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
How helpful was this page ?
Rated 5, based on 2 reviews.
POST A COMMENT

NITIN, posted on 12 Jun 20 12:25 PM

VERY NICE AND USEFUL INFORMATION C

1 - 1 of 1